Evogene Ltd. EVGN is amending its collaboration with Bayer AG BAYRY's crop science division to identify genome editing targets for evaluation against a broad range of corn diseases.
The collaboration aims to develop improved corn seeds with resistance to fungal diseases.
Evogene said it will use its computational predictive biology platform to identify required edits to improve disease resistance in corn.
The overall annual value loss from corn diseases in the U.S. alone is estimated at close to $7 billion, according to Evogene.
Evogene shares were trading up 3.90% at $1.60 in Tuesday’s pre-market session.
Related Links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
